公开(公告)号：EP3548096A1

公开(公告)日：2019-10-09

申请号：EP17825989.1

申请日：2017-11-29

申请人： Memorial Sloan Kettering Cancer Center ,  Cornell University ,  The Curators of the University of Missouri

发明人： BRADBURY, Michelle S. ,  QUINN, Thomas P. ,  YOO, Barney ,  WEBER, Wolfgang ,  TOUIJER, Karim ,  SCHER, Howard ,  MA, Kai ,  WIESNER, Ulrich

IPC分类号： A61K49/00 ,  A61K51/08 ,  A61K51/12 ,  C07K7/00

公开(公告)号：EP3302568A1

公开(公告)日：2018-04-11

申请号：EP16730103.5

申请日：2016-05-26

申请人： Memorial Sloan Kettering Cancer Center ,  Cornell University

发明人： BRADBURY, Michelle S. ,  WIESNER, Ulrich ,  OVERHOLTZER, Michael ,  SCHER, Howard ,  MA, Kai

IPC分类号： A61K47/48 ,  A61P35/00

CPC分类号： A61K47/6929 ,  A61K38/22 ,  A61K47/60 ,  A61K47/6923

摘要： Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

公开(公告)号：EP3989949A1

公开(公告)日：2022-05-04

申请号：EP20830832.0

申请日：2020-06-26

申请人： Board of Regents, The University of Texas System ,  Memorial Sloan Kettering Cancer Center

发明人： GIANCOTTI, Filippo ,  OUERFELLI, Ouathek ,  SU, Wenjing ,  YANG, Guangli ,  SCHER, Howard ,  MARZABADI, Mohammad

IPC分类号： A61K31/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61P43/00 ,  C07K16/28

公开(公告)号：EP2885428A1

公开(公告)日：2015-06-24

申请号：EP13829156.2

申请日：2013-08-19

申请人： Memorial Sloan Kettering Cancer Center

发明人： SCHER, Howard ,  FLEISHER, Martin ,  DANILA, Daniel

IPC分类号： C12Q1/68 ,  C12Q1/02 ,  G01N33/574 ,  C07K14/00 ,  A61K39/395

CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N2800/52

摘要： Using an RT-PCR platform, detection of gene transcripts highly expressed in prostate tissue and expressed in peripheral blood mononuclear cells (PBMC) from patients with mCRPC can provide a more reliable and robust prediction of poor overall survival than that of CTC enumeration in mCRPC. Disclosed is the identification of five genes, KLK3, KLK2, HOXB13, GHRL2 and FOXA1, the detection of two (2) or more transcripts of which predicts overall poor survival. The test is performed on blood samples that have been collected in collection tubes that stabilize intracellular RNA, require minimal on-site processing and can be easily stored and shipped for subsequent extraction of total RNA from whole blood for RT-PCR.